Navigation Links
GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research
Date:12/4/2008

NEW ROCHELLE, N.Y., Dec. 4 /PRNewswire/ -- Researchers are taking a closer look at the phosphoinositide 3-kinase (PI3-kinase) pathway as studies continue to demonstrate that inhibiting this biological route suppresses tumor growth, reports Genetic Engineering & Biotechnology News (GEN). The pathway is involved in angiogenesis, cell growth, differentiation, and survival. In addition, it is part of the PI3/AKT/mTOR pathway, which plays a key role in cancer, according to the December issue of GEN (www.genengnews.com).

"The good news about cancer is that a report last month from the National Cancer Institute indicated that there is a decline in both cancer incidence and death rates in the U.S.," says John Sterling, Editor in Chief of GEN. "But the American Cancer Society estimates that there will still be over half a million cancer deaths in America in 2008 so novel therapies remain critical."

Exelixis, for example, has developed several potential cancer compounds, two of which (XL147 and XL765) target the PI3-kinase pathway. Company scientists say they are studying the pathway because there are a number of feedback loops that emanate from m-TOR and downstream kinases that circle back to the top of the pathway and turn on AKT, an enzyme that drives tumor survival signals.

Investigators at the University of London are exploring the role of PI3-kinase isoforms in normal physiology and disease. A team led by Dr. Bart Vanhaesebroeck isolated the PI3-kinase genes in various mammals and developed models to better understand gene function.

Also covered in the GEN article is research taking place at Eli Lilly, the Multiple Myeloma Research Foundation, Semafore Pharmaceuticals, Calistoga Pharmaceuticals, and Harvard Medical School.

For a copy of the December issue of GEN, please call (914) 740-2122, or email: ebicovny@liebertpub.com

Genetic Engineering & Biotechnology News (www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Clinical Research and Diagnostics.

Contact: John Sterling, Editor in Chief, Genetic Engineering & Biotechnology News (914) 740-2196, jsterling@genengnews.com


'/>"/>
SOURCE Genetic Engineering & Biotechnology News
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... ... September 24, 2019 , ... ... advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, ... biopharmaceutical company focused on the development of therapies to treat central nervous ...
(Date:9/17/2019)... ... September 17, 2019 , ... Catalent, a global ... Clinical Supplies Management, Asia Pacific (APAC) will present at the upcoming 3rd Annual ... 25-26, 2019. , On Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney will ...
(Date:9/17/2019)... JUPITER, Fla. (PRWEB) , ... September 16, 2019 ... ... will broadcast Nationwide via CNBC on Saturday, September 21st @11:00am ET. Check local ... Credo Biomedical Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore ...
(Date:9/11/2019)... , ... September 10, 2019 , ... ... manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced ... be held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. ...
Breaking Biology Technology:
(Date:9/30/2019)... ... September 30, 2019 , ... ... supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, today announced ... to “Ready-to-Print” (RTP) cellular product formats (patent number AU 2015259373). This new ...
(Date:9/25/2019)... (PRWEB) , ... September 25, 2019 , ... ... biopharma leaders through off-the-record collaboration and dialogue, today announces its inaugural South ... Orleans BioInnovation Center in Louisiana. , Co-produced by Tulane University, this invitation-only ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... interactions for accelerated drug development, announced today that it has raised $2.8M from ... OS Fund and also includes AME Cloud Ventures, Boom Capital, Madrona Venture Group, ...
Breaking Biology News(10 mins):